News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,924 Results
Type
Article (40018)
Company Profile (250)
Press Release (664655)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204282)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81140)
Employer Resources (172)
FDA (16250)
Job Trends (14887)
News (345507)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1445)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2870)
Cardiovascular disease (213)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66860)
Collaboration (1014)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2624)
CRISPR (56)
C-suite (329)
Cystic fibrosis (112)
Data (3002)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6424)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (127)
Earnings (87461)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113748)
Executive appointments (845)
FDA (17907)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (375)
GLP-1 (783)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (9)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (494)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (90)
Medical device (13465)
Medtech (13470)
Mergers & acquisitions (19583)
Metabolic disorders (849)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2122)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (428)
Opinion (217)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (299)
Patient recruitment (166)
Peanut (50)
People (57690)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29450)
Phase III (21920)
Pipeline (1637)
Policy (200)
Postmarket research (2563)
Preclinical (8871)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (458)
Real estate (5917)
Recruiting (66)
Regulatory (22637)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (89)
Last 7 days (350)
Last 30 days (1830)
Last 365 days (31170)
2025 (16820)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38212)
Australia (6232)
California (7444)
Canada (2360)
China (671)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82112)
Florida (1119)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (638)
India (27)
Indiana (361)
Iowa (16)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1023)
Massachusetts (5531)
Michigan (246)
Minnesota (451)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2080)
New Mexico (28)
New York (2085)
North Carolina (1080)
North Dakota (8)
Northern California (3279)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1612)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2785)
Tennessee (126)
Texas (1127)
United States (27586)
Utah (220)
Virginia (186)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
704,924 Results for "otonomy inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Otonomy Announces Change in Stock Exchange Listing
Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022.
December 22, 2022
·
1 min read
Deals
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.
March 29, 2023
·
4 min read
Business
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Otonomy, Inc. reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities.
November 10, 2022
·
7 min read
Biotech Beach
Otonomy Provides Corporate Update - December 19, 2022
Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.
December 19, 2022
·
6 min read
Press Releases
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
July 15, 2025
·
13 min read
Biotech Beach
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy, Inc. announced that management will participate in the following virtual investor conference events.
February 28, 2022
·
1 min read
Biotech Beach
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced its participation in the H.C. Wainwright Global Investment Conference.
May 18, 2022
·
1 min read
Press Releases
CoRegen, Inc. Closes More Than $93 Million Financing
July 10, 2025
·
3 min read
1 of 70,493
Next
